• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1401581 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 ?( l% g  N3 P4 Y, u, hNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ! ?: \( F  C4 j8 ]3 h
+ Author Affiliations
& d; E' z  ?! n$ s7 l
3 ^( e% m" E, p' E1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan * o) n% }  X. e, w- X! z" N; H
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
! F7 M1 ?; t9 P# m5 v3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
. b, d- X7 `2 a3 J4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
' [! Y8 b! R1 h* F0 M; [5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
& O: N9 k% v$ J* C$ @" b6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
. H, e) ?& U7 z1 S. Q1 o7Kinki University School of Medicine, Osaka 589-8511, Japan % O/ T' A. {. V" O; @
8Izumi Municipal Hospital, Osaka 594-0071, Japan 8 Q- ^# q5 w! P0 C. _# l( E. g
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 0 P  X2 R* P* j9 |3 W- L
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp - u6 W9 n  `. L9 S1 W: O
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. / v, G, L; {( Q* o6 Y" \' l* b
. g5 X) b# d4 ~9 x% o2 V8 v, A* |
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
/ E( {+ m- g4 F; V
3 |; H+ u5 l3 u( f# E/ }) PAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
6 h: |& n! O8 ^- G3 a) ^) X- \# j- N% u
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  . q* d" Z9 X/ ?

( s7 ?' [; o& T) v( C9 ?- b5 WPublished online on: Thursday, December 1, 2011 , F' s; o8 }4 ?- V  W& m6 v
- r" \: B- W8 x; f
Doi: 10.3892/ol.2011.507 ' [' F; F/ G$ Y! I+ r& ~# c; `
6 o5 |6 d' O( d3 V/ B- i: o6 ?2 N. z
Pages: 405-410
$ J. M+ ~1 n9 k" h7 z1 ?7 Z$ w# Z4 f6 s9 `+ K
Abstract:- E( @$ T. k! h. K
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
( O5 x: C: i9 c- V+ C. u& N9 q
; Q4 z. O4 l+ i1 s, l) R% S; L* D
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population2 R1 H/ D3 E3 z
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 1 Z& ^  T( H# n0 h6 |) q! Q. p2 s
+ Author Affiliations
' R5 _% f  A+ j8 ^7 R4 j9 j3 e3 q8 J1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
2 w2 ]6 X) |8 }9 x2Department of Thoracic Surgery, Kyoto University, Kyoto , r  `0 s" D4 Q0 [2 V( V. p
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan ; Z- j( F/ E4 U! [. Z
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp / r5 q( `3 K/ E
Received September 3, 2010.
3 g7 {4 n4 o4 A/ W5 N/ m4 VRevision received November 11, 2010. ! G' r. m9 z" W6 P0 A
Accepted November 17, 2010. 2 v7 E2 N5 {& K2 Z8 H: ?( i% M  \
Abstract
4 N0 m  P7 w( W! S  E- eBackground: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
. d. Y, e5 E. m- K% S) C8 @! }0 f! `Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ! i: }2 U% U8 Z$ L/ v( K
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 6 F/ B: O  @/ W3 L1 _' z9 F
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
( H4 u2 V3 e* m/ `) L8 L0 x
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。$ Q! _" `. o3 Z' p
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
$ Y6 t9 g# K2 @- d0 U
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
( o/ }1 `; @4 b6 @9 m3 bhttp://clinicaltrials.gov/ct2/show/NCT01523587  I* n# @9 D$ ^8 ?) g( B8 k) M

$ [" N* K5 |9 _$ RBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC% c. U4 Q; D# c3 s
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 # k1 p: N+ Q) f7 O1 B" u6 h; D
4 y) X3 Z; v5 m' d4 q
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。9 Y8 ~4 A% L6 l" t7 m) _1 V: B
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
$ X5 D6 r) _' y* E, \从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
& w% g4 }  e' z! G至今为止,未出 ...

$ {( E6 J+ O) l2 p9 ?1 |没有副作用是第一追求,效果显著是第二追求。0 _2 f! M) H+ d( V( k1 W6 O2 \
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表